News

The best biotech growth stocks typically have one clear-cut value driver. This fact is a testament to the extreme difficulty involved in bringing a major new drug to market and subsequently

You can earn monthly dividend income in a few ways:

Today, I look at three blue chip stocks that are trading at reasonable valuations and will have you receiving a dividend paycheck every month. One

You can earn monthly dividend income in a few ways:

Today, I look at three blue chip stocks that are trading at reasonable valuations and will have you receiving a dividend paycheck every month. One

When looking for bargains at a store, you might go to the sale rack. With the stock market, you might look to some of the stocks that have tumbled over the past several months. Even though the three

When looking for bargains at a store, you might go to the sale rack. With the stock market, you might look to some of the stocks that have tumbled over the past several months. Even though the three

Artificial intelligence (AI) is getting heaps of attention on Wall Street, but that doesn't mean it's the only innovative investment opportunity right now. Shares of plenty of companies that aren't

Investor enthusiasm can wax and wane -- sometimes dramatically. Consider CRISPR Therapeutics (NASDAQ: CRSP), which is trading for around $61 a share, down from its high of $220.20 on Jan. 15, 2021.

Investor enthusiasm can wax and wane -- sometimes dramatically. Consider CRISPR Therapeutics (NASDAQ: CRSP), which is trading for around $61 a share, down from its high of $220.20 on Jan. 15, 2021.

Investor enthusiasm can wax and wane -- sometimes dramatically. Consider CRISPR Therapeutics (NASDAQ: CRSP), which is trading for around $61 a share, down from its high of $220.20 on Jan. 15, 2021.

Biotech investors like it when one of their companies reports gains in a developmental program, and that was the dynamic behind Tuesday's rise in the share price of Aclaris Therapeutics (NASDAQ:

Shares of Surmodics (NASDAQ: SRDX) were up 16% early Tuesday afternoon as the healthcare company, which provides chemicals for in vitro diagnostic immunoassay tests and makes coatings for

Biotech growth stocks are inherently risky due to the plethora of competitive, financial, clinical, and regulatory hurdles unique to the industry. Despite these various risk factors, however, most

CRISPR Therapeutics (NASDAQ: CRSP) and partner Vertex Pharmaceuticals just took another step closer to launching a potential game-changing product. At the same time, the U.S. Food and Drug

CRISPR Therapeutics (NASDAQ: CRSP) and partner Vertex Pharmaceuticals just took another step closer to launching a potential game-changing product. At the same time, the U.S. Food and Drug

CRISPR Therapeutics (NASDAQ: CRSP) and partner Vertex Pharmaceuticals just took another step closer to launching a potential game-changing product. At the same time, the U.S. Food and Drug

Shares of Omeros (NASDAQ: OMER) were down 12.9% early Monday afternoon after the clinical-stage biopharmaceutical company released a presentation it made regarding a therapy to treat a rare blood

These days, investors can find plenty of reasons to feel nervous about buying stocks. Surging inflation, soaring interest rates, and geopolitical tensions are all legitimate concerns for most

Pharmaceutical companies Novo Nordisk (NYSE: NVO) and AbbVie (NYSE: ABBV) seem to be headed in separate directions.

Denmark-based Novo Nordisk, thanks to growing sales of diabetes drug Ozempic and